1-3 of 3
Timothy H. J. Goodship, MD
Close
Sort by
Journal Articles

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.

Samhar I. Al-Akash, Timothy H. J. Goodship, MD, Richard J. H. Smith, MD, Christophe M. Legendre, MD, Christoph Licht, MD, Petra Muus, MD, PhD, Camille L. Bedrosian, MD, Veronique Frémeaux-Bacchi, PhD, Chantal Loirat, MD
Journal: Blood
Blood (2012) 120 (21): 2085.
https://doi.org/10.1182/blood.V120.21.2085.2085
Published: 2012
Journal Articles

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe M. Legendre, MD, Kenneth W. Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD
Journal: Blood
Blood (2012) 120 (21): 985.
https://doi.org/10.1182/blood.V120.21.985.985
Published: 2012
Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, MD, Kenneth W Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L Bedrosian, MD, Chantal Loirat, MD
Journal: Blood
Blood (2011) 118 (21): 3303.
https://doi.org/10.1182/blood.V118.21.3303.3303
Published: 2011